Nanotech

Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors

Expect to initiate Phase 1b combination study of NUV-868 by the end of 2022

On track to nominate first clinical candidate from Drug-Drug Conjugate (DDC) platform by the end of 2022

Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securities of $673.9 million as of September 30, 2022

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2022, and provided a business update.

"We are encouraged by the continued clinical progress of NUV-868 and look forward to the initiation of Phase 1b combination cohorts later this year, which we anticipate will provide better understanding of the potential benefit this therapy can offer a wide range of patients with advanced solid tumors," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "We also expect to nominate the first clinical candidate from our DDC platform by the end of 2022, underscoring the growth-driving capabilities of this platform as we work to tackle some of the greatest unmet needs in oncology."

Recent Business Updates

NUV-868, BD2-Selective BETi : Advanced solid tumors

  • Dosing ongoing in the Phase 1 monotherapy study of NUV-868. Nuvation Bio continues to enroll the Phase 1 monotherapy study in advanced solid tumors. The Company expects to initiate the Phase 1b study of NUV-868 in combination with olaparib in ovarian, pancreatic, metastatic castration-resistant prostate and triple negative breast cancers, or in combination with enzalutamide in metastatic castration-resistant prostate cancer, by the end of 2022.

Drug-Drug Conjugate Platform: Solid tumors

  • Nomination of first clinical candidate from the DDC platform is expected by the end of 2022.

Third Quarter 2022 Financial Results

As of September 30, 2022, Nuvation Bio had cash, cash equivalents and marketable securities of $673.9 million.

For the three months ended September 30, 2022, research and development expenses were $21.3 million, compared to $17.1 million for the three months ended September 30, 2021. The increase was primarily due to restructuring costs of $1.6 million related to severance and benefit costs and $5.7 million related to contract termination costs offset by $2.8 million decrease in third-party costs related to research services and manufacturing, as well as a $0.3 million decrease in personnel-related costs driven by the termination of the NUV-422 program.

For the three months ended September 30, 2022, general and administrative expenses were $8.0 million, compared to $5.7 million for the three months ended September 30, 2021. The increase was primarily due to a $1.9 million increase in personnel-related costs driven by an increase in headcount and stock-based compensation, a $0.2 million increase in occupancy expenses, a $0.1 million increase in professional fees, and a $0.1 million of restructuring costs related to severance and benefit costs.

For the three months ended September 30, 2022, Nuvation Bio reported a net loss of $27.2 million, or $(0.12) per share. This compares to a net loss of $22.0 million, or $(0.11) per share, for the comparable period in 2021.

About Nuvation Bio

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com .

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the expected timing of clinical trial initiation, the expected timing of clinical candidate nomination from the DDC platform, Nuvation Bio's cash runway and the potential therapeutic benefit of its product candidates. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; risks related to cost reduction efforts; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q to be filed with the SEC on or about November 3, 2022, under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Nuvation Bio Inc. and Subsidiaries
Consolidated Balance Sheets
Unaudited
(In thousands, except share and per share data) September 30, December 31,

2022

2021

Assets
Current assets:
Cash and cash equivalents

$

138,690

$

132,423

Prepaid expenses and other current assets

5,094

3,642

Marketable securities

535,255

632,969

Interest receivable on marketable securities

2,350

3,039

Total current assets

681,389

772,073

Property and equipment, net

902

786

Operating lease right-of-use assets

4,060

2,871

Lease security deposit

138

421

Total assets

$

686,489

$

776,151

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

$

2,995

$

3,925

Current operating lease liabilities

1,100

863

Accrued expenses

9,916

12,137

Total current liabilities

14,011

16,925

Warrant liability

1,171

11,037

Non-current operating lease liabilities

3,372

2,192

Total liabilities

18,554

30,154

Stockholders' equity
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000
(Class A 1,000,000,000, Class B 60,000,000) shares authorized as of September 30, 2022 and December 31, 2021,
218,392,607 (Class A 217,392,607, Class B 1,000,000) and 217,948,568 (Class A 216,948,568, Class B 1,000,000)
shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively

922,209

909,985

Accumulated deficit

(246,157

)

(162,803

)

Accumulated other comprehensive income

(8,117

)

(1,185

)

Total stockholders' equity

667,935

745,997

Total liabilities and stockholders' equity

$

686,489

$

776,151

Nuvation Bio Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data)
Three Months Ended September 30, Nine Months Ended September 30,

2022

2021

2022

2021

Operating expenses:
Research and development

$

21,294

$

17,122

$

70,944

$

47,035

General and administrative

8,044

5,669

24,455

16,674

Total operating expenses

29,338

22,791

95,399

63,709

Loss from operations

(29,338

)

(22,791

)

(95,399

)

(63,709

)

Other income (expense):
Interest income

2,127

847

3,925

2,061

Investment advisory fees

(263

)

(170

)

(647

)

(454

)

Change in fair value of warrant liability

462

125

9,866

332

Realized (loss) gain on marketable securities

(191

)

10

(1,099

)

56

Total other (expense) income, net

2,135

812

12,045

1,995

Loss before income taxes

(27,203

)

(21,979

)

(83,354

)

(61,714

)

Provision for income taxes

-

-

-

-

Net loss

$

(27,203

)

$

(21,979

)

$

(83,354

)

$

(61,714

)

Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic and diluted

$

(0.12

)

$

(0.11

)

$

(0.39

)

$

(0.32

)

Weighted average common shares outstanding, basic and diluted

218,300

207,101

216,123

193,730

Comprehensive loss:
Net loss

$

(27,203

)

$

(21,979

)

$

(83,354

)

$

(61,714

)

Other comprehensive income, net of taxes:
Unrealized loss on available-for-sale securities

(1,139

)

(369

)

(6,932

)

(1,169

)

Comprehensive loss

$

(28,342

)

$

(22,348

)

$

(90,286

)

$

(62,883

)

Nuvation Bio Investor Contact:
ir@nuvationbio.com

Nuvation Bio Media Contact:
Argot Partners
Leo Vartorella
leo@argotpartners.com

News Provided by Business Wire via QuoteMedia

NUVB
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

Phase 1b study designed to determine the safety and dose of NUV-868 in combination with olaparib or enzalutamide for the treatment of advanced solid tumors

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced it has dosed the first patient in a Phase 1b study of its BD2-selective BET inhibitor, NUV-868, in combination with olaparib.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney

Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors

Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securities of $703.8 million as of June 30, 2022

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Company prioritizes NUV-868, its BD2 selective BET inhibitor currently in a Phase 1 dose escalation study in advanced solid tumors, and its novel small molecule Drug-Drug Conjugate (DDC) platform

Company restructuring and cost savings associated with NUV-422 program discontinuation to extend cash runway through 2028

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Dr. Liu is a clinical leader who brings expertise in the discovery, development, and regulatory approval of oncology therapies worldwide

Ms. Wentworth has over two decades of industry experience in domestic and international regulatory and quality affairs

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

NanoXplore Inc. to Host Second Quarter 2023 Results Webcast on February 15, 2023

NanoXplore Inc. (" NanoXplore " or the " Company ") (TSX: GRA and OTCQX: NNXPF) is pleased to hold a webcast to discuss the results of its second quarter ended December 31, 2022, on Wednesday, February 15, 2023, at 8:30 a.m. (Eastern Time). The financial results will be released on Tuesday February 14, 2023, after market close.

Details of the Q2 Webcast

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Anixa Biosciences Inc.

Anixa Biosciences Inc.

Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.

NanoXplore Announces Appointment of New Board Member

NanoXplore Inc. ("NanoXplore" or the "Corporation") ( TSX: GRA and OTCQX: NNXPF ), a world-leading graphene company, announces the nomination of Ms. Catherine Loubier to its Board of Directors.

The nomination of Ms. Loubier followed an extensive search process by the Corporate Governance and Nominating Committee of the Board. The Board will continue to ensure its composition is well aligned to support senior management with the execution of its new five-year strategic growth plan and with the next phase of the Company's growth.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NanoXplore Reports First Quarter 2023 Results and Unveils Its 5-year Strategic Plan

NanoXplore Inc. ("NanoXplore" or "the Corporation") (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, reported today financial results for the first quarter ended September 30, 2022, and unveiled its 5-year strategic plan.

All amounts in this press release are in Canadian dollars, unless otherwise stated.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NanoXplore Inc. to Release First Quarter Results and 5-Year Strategic Plan on November 14, 2022, After Market Close

NanoXplore Inc. (" NanoXplore " or the " Company ") (TSX: GRA and OTCQX: NNXPF) is pleased to hold a webcast to discuss the results of its first quarter ended September 30, 2022, on Tuesday, November 15, 2022, at 8:30 a.m. Eastern Time. The financial results and the 5-year strategic plan will be released on Monday November 14, 2022, after the market close.

Details of the Q1 Webcast

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Why Invest in Nanotech Stocks?

Why Invest in Nanotech Stocks?

The nanotechnology market is experiencing a promising stage of growth, making it an attractive space for investors.

From nanotech-based solar panels that increase energy efficiency to pharmaceutical products that make use of nanotech in drug-delivery systems, nanotechnology has far-reaching effects that are quickly transforming the world as we know it. Graphene-based nanomaterials also have applications across a wide range of industries, including renewable energy and medicine.

Here the Investing News Network provides a brief overview of what nanotech is, what the market looks like right now and what the nanotech industry's future could be. Read on to see if investing in nanotech stocks could work for your portfolio.

Keep reading...Show less

Latest Press Releases

Related News

×